A randomised, assessor-blind, controlled phase 3 non-inferiority trial assessing the efficacy and safety of individualised follitropin delta dosing regimen in Japanese IVF/ICSI patients

被引：0
|
作者：
Ishihara, O. [1 ]
Kitamura, M. [2 ]
Arce, J. C. [3 ]
机构：
[1] Saitama Med Univ, Dept Obstet & Gynaecol, Moroyama, Saitama, Japan
[2] Ferring Pharmaceut, Dev, Tokyo, Japan
[3] Ferring Pharmaceut, Reprod Med & Maternal Hlth, Copenhagen, Denmark
来源：
HUMAN REPRODUCTION | 2020年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
P-566
引用
收藏
页码：I397 / I397
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety of moxidectin compared to ivermectin against Strongyloides stercoralis infection in Laotian and Cambodian adults: A randomised, doubleblind, non-inferiority, phase 2/3 trial
    Sprecher, Viviane
    Hofmann, Daniela
    Sayasone, Somphou
    Khieu, Virak
    Hattendorf, Jan
    Keiser, Jennifer
    [J]. TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2023, 28 : 131 - 132
  • [32] Efficacy and safety of ferric citrate hydrate compared with sodium ferrous citrate in Japanese patients with iron deficiency anemia: a randomized, double-blind, phase 3 non-inferiority study
    Komatsu, Norio
    Arita, Kojo
    Mitsui, Hironori
    Nemoto, Takanori
    Hanaki, Koji
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 114 (01) : 8 - 17
  • [33] Efficacy and safety of ferric citrate hydrate compared with sodium ferrous citrate in Japanese patients with iron deficiency anemia: a randomized, double-blind, phase 3 non-inferiority study
    Norio Komatsu
    Kojo Arita
    Hironori Mitsui
    Takanori Nemoto
    Koji Hanaki
    [J]. International Journal of Hematology, 2021, 114 : 8 - 17
  • [34] Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial
    Clarke, Ed
    Bashorun, Adedapo
    Adigweme, Ikechukwu
    Hydara, Mariama Badjie
    Umesi, Ama
    Futa, Ahmed
    Ochoge, Magnus
    Obayemi, Dolapo
    Edem, Bassey
    Saidy-Jah, Ebrima
    Onwuchekwa, Chukwuemeka
    Dhere, Rajeev
    Sethna, Vistasp
    Kampmann, Beate
    Goldblatt, David
    Taylor, Douglas
    Andi-Lolo, Indah
    Hosken, Nancy
    Antony, Kalpana
    Innis, Bruce L.
    Alderson, Mark R.
    Lamola, Steve
    [J]. LANCET INFECTIOUS DISEASES, 2021, 21 (06): : 834 - 846
  • [35] Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial
    Kollef, Marin H.
    Novacek, Martin
    Kivistik, Ulo
    Rea-Neto, Alvaro
    Shime, Nobuaki
    Martin-Loeches, Ignacio
    Timsit, Jean-Francois
    Wunderink, Richard G.
    Bruno, Christopher J.
    Huntington, Jennifer A.
    Lin, Gina
    Yu, Brian
    Butterton, Joan R.
    Rhee, Elizabeth G.
    [J]. LANCET INFECTIOUS DISEASES, 2019, 19 (12): : 1299 - 1311
  • [36] Efficacy and safety of moxidectin and albendazole compared with ivermectin and albendazole coadministration in adolescents infected with Trichuris trichiura in Tanzania: an open-label, non-inferiority, randomised, controlled, phase 2/3 trial
    Welsche, Sophie
    Mrimi, Emmanuel C.
    Hattendorf, Jan
    Huerlimann, Eveline
    Ali, Said M.
    Keiser, Jennifer
    [J]. LANCET INFECTIOUS DISEASES, 2023, 23 (03): : 331 - 340
  • [37] Efficacy and safety of azithromycin versus placebo to treat lower respiratory tract infections associated with low procalcitonin: a randomised, placebo-controlled, double-blind, non-inferiority trial
    Tsalik, Ephraim L.
    Rouphael, Nadine G.
    Sadikot, Ruxana T.
    Rodriguez-Barradas, Maria C.
    McClain, Micah
    Wilkins, Dana M.
    Woods, Christopher W.
    Swamy, Geeta K.
    Walter, Emmanuel B.
    El Sahly, Hana M.
    Keitel, Wendy A.
    Mulligan, Mark J.
    Tuyishimire, Bonifride
    Serti, Elisavet
    Hamasaki, Toshimitsu
    Evans, Scott R.
    Ghazaryan, Varduhi
    Lee, Marina S.
    Lautenbach, Ebbing
    [J]. LANCET INFECTIOUS DISEASES, 2023, 23 (04): : 484 - 495
  • [38] Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study
    Inagaki, Nobuya
    Onouchi, Hitoshi
    Maezawa, Hideaki
    Kuroda, Shingo
    Kaku, Kohei
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2015, 3 (03): : 191 - 197
  • [39] Correction: Efficacy and safety of ferric citrate hydrate compared with sodium ferrous citrate in Japanese patients with iron deficiency anemia: a randomized, double-blind, phase 3 non-inferiority study
    Norio Komatsu
    Kojo Arita
    Hironori Mitsui
    Takanori Nemoto
    Koji Hanaki
    [J]. International Journal of Hematology, 2024, 119 : 472 - 472
  • [40] Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial
    Eron, Joseph J., Jr.
    Rockstroh, Juergen K.
    Reynes, Jacques
    Andrade-Villanueva, Jaime
    Ramalho-Madruga, Jose Valdez
    Bekker, Linda-Gail
    Young, Benjamin
    Katlama, Christine
    Maria Gatell-Artigas, Jose
    Arribas, Jose R.
    Nelson, Mark
    Campbell, Havilland
    Zhao, Jing
    Rodgers, Anthony J.
    Rizk, Matthew L.
    Wenning, Larissa
    Miller, Michael D.
    Hazuda, Daria
    DiNubile, Mark J.
    Leavitt, Randi
    Isaacs, Robin
    Robertson, Michael N.
    Sklar, Peter
    Nguyen, Bach-Yen
    [J]. LANCET INFECTIOUS DISEASES, 2011, 11 (12): : 907 - 915
12345